Welcome to Prestigio Registry platform

ICAR 2024

2024-06-21

Post-translational HIV-1 integrase modification sites might be affected by complex and prolonged treatment history associated with multidrug resistance: a proof of concept study from the PRESTIGIO registry

D.Armenia, V.Spagnuolo, L.Galli, T.Clemente, R.Lolatto, D.Minisci, L.Pagnucco, R.Pincino, V.Malagnino, T.Mulas, L.Sarmati, M.Zazzi, M.M.Santoro, A.Castagna

ICAR 2024

2024-06-20

Network analysis of proviral DNA mutations in People with 4-class-resistant HIV-1: Data from the PRESTIGIO Registry

S.Diotallevi, D.Armenia, T.Clemente, F.Saladini, S.Rusconi, L.Calza, A.Cervo, M.Zazzi, R.Lolatto, M.C.Bellocchi, G.Marchegiani, L.Carioti, E.Fronti, M.Fiscon, V. Spagnuolo, A.Castagna, M.M.Santoro, L.Farina for the PRESTIGIO Registry GROUP

ICAR 2024

2024-06-19

Multidrug resistance is associated with different gene methylation in people with HIV: a matched cohort study with data from the PRESTIGIO Registry

T.Clemente, G.M.Scotti, E.Guidi, A.Cervo, S.Rusconi, G.C.Marchetti, S.Diotallevi, S.Bagaglio, R.Lolatto, M.Tavio, C.Torti, B.M.Celesia, A.Castagna, V.Spagnuolo, on the behalf of the PRESTIGIO Study Group

ICAR 2024

2024-06-19

HIV acquisition at birth does not drive T-cell dysfunction in Heavily Treatment Experienced (HTE): data from the PRESTIGIO Registry

V.Bono, C.Tincati, V.Spagnuolo, L.Galli, A.Di Biagio, M.Augello, R.Rovito, E.Garlassi, M.C.Moioli, E.Focà, A.Castagna, G.Marchetti

CROI 2024

2024-03-03

Teropavimab and Zinlirvimab Sensitivity in People Living With MDR HIV-1: PRESTIGIO Registry Data

V.Spagnuolo, L.Galli, A.Parvangada, K.J.Dunn, F.Lagi, R.Gagliardini, L.Sarmati, A.Cattelan, A.Giacomelli, M.M.Santoro, M.Zazzi, C.Callebaut, A.Castagna, L.VanderVeen

EACS 2023

2023-10-20

Risk of virological failure after drug burden reduction in non-viremic people with 4-class drug-resistant HIV: data from the PRESTIGIO Registry

T.Clemente, S.Diotallevi, R.Lolatto, R.Gagliardini, A.Giacomelli, M.Malena, M.Ferrara, A.Cervo, L.Calza, F.Maggiolo, S.Rusconi, M.M.Santoro, A.Castagna, V.Spagnuolo on behalf of the PRESTIGIO Study Group

EACS 2023

2023-10-19

Polypharmacy, anticholinergic burden, and drug-drug interaction assessment in people living with HIV harboring a 4-class resistance: data from the PRESTIGIO Registry

M.Mazzitelli, D.Pontillo, T.Clemente, A.di Biagio, G.Cenderello, S.Rusconi, B.Menzaghi, C.Fornabaio, E.Garlassi, M.Zazzi, A.Castagna, A.Cattelan

EACS 2023

2023-10-19

Efficacy and durability of Fostemsavir-, Ibalizumab-, or Lenacapavir-including regimens in people living with a Multidrug Resistant HIV: results from the PRESTIGIO Registry

G.Torkjazi, L.Galli, R.Gagliardini, M.Feasi, S.Bonora, F.Lagi, E.Focà, G.Marchetti, A.Cervo, F.Maggiolo, R.Gulminetti, F Vichi, R.Papaioannu Borjesson, A.Castagna, V.Spagnuolo

EACS 2023

2023-10-19

Do minority resistant variants in HIV-DNA predict virological rebound in highly treatment experienced PLWH under virological control: Data from the PRESTIGIO Registry

D.Armenia, V.Spagnuolo, M.C.Bellocchi, L.Galli, L.Duca, G.Marchegiani, T.Clemente2, L.Carioti3, R.Lolatto, L.Calza, B.M.Celesia, A.Cascio, D.Francisci, A.Saracino, C.Torti , M.Zazzi, A.Castagna, M.M.Santoro on behalf of the PRESTIGIO Registry

IAS 2023

2023-07-24

Heavily Treatment-Experienced (HTE) HIV-Infected Individuals with Vertical Transmission and Detectable Viremia do not Display Increased Peripheral Inflammation Markers: Data from the PRESTIGIO Registry

V.Bono, V.Spagnuolo, L.Galli, A.di Biagio, M.Augello, R.Rovito, G.Elisa, M.C.Moioli, E.Focà, C.Tincati, A.Castagna, G.Marchetti

ICAR 2023

2023-06-16

Does NGS on HIV-1 DNA improve resistance assessment in highly treatment-experienced and multi-resistant individuals under virological control? An experience from the PRESTIGIO Registry

D.Armenia, V.Spagnuolo, M.C.Bellocchi, L.Galli, L.Duca, G.Marchegiani, T.Clemente, L.Carioti, R.Lolatto, L.Calza, B.M.Celesia, A.Cascio, D.Francisci, A.Saracino, C.Torti, M.Zazzi, A.Castagna, M.M.Santoro, on behalf of the PRESTIGIO Registry

ICAR 2023

2023-06-15

Malignancies and MACEs in the PRESTIGIO Registry

T.Clemente, D.Pontillo, D.Minisci, A.Di Biagio, A.Galli, L.Attala, G.Cenderello, V.Malagnino, S.Lo Caputo, M.Tavio, A.Giacomelli, A.Castagna, V.Spagnuolo, on behalf of the PRESTIGIO Study Group

ICAR 2023

2023-06-15

Lower AIDS-related hospitalizations in women living with HIV multidrug resistance: results from the PRESTIGIO registry

R.Papaioannu Borjesson, L.Galli, R.Lolatto, B.Menzaghi, M.Feasi, R.Gulminetti, C.Fornabaio, A.M.Cattelan, S.Bonora, F.Lagi, M.Zazzi, A.Castagna, on behalf of PRESTIGIO Study Group